Blasco, LuciaAmbroa, AntonLopez, MariaFernandez-Garcia, LauraBleriot, InesTrastoy, RocioRamos-Vivas, JoseCoenye, TomFernandez-Cuenca, FelipeVila, JordiMartinez-Martinez, LuisRodriguez-Baño, JesusPascual, AlvaroCisneros, Jose MiguelPachon, JeronimoBou, GermanTomas, Maria2023-02-082023-02-082019-11-09Blasco L, Ambroa A, Lopez M, Fernandez-Garcia L, Bleriot I, Trastoy R, et al. Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii. Microorganisms. 2019 Nov 12;7(11):5562076-2607http://hdl.handle.net/10668/14690Phage therapy is an abandoned antimicrobial therapy that has been resumed in recent years. In this study, we mutated a lysogenic phage from cinetobacter baumannii into a lytic phage (Ab105-2phi∆CI) that displayed antimicrobial activity against A. baumannii clinical strain Ab177_GEIH-2000 (isolated in the GEIH-REIPI Spanish Multicenter A. baumannii Study II 2000/2010, Umbrella Genbank Bioproject PRJNA422585, and for which meropenem and imipenem MICs of respectively, 32 µg/mL, and 16 µg/mL were obtained). We observed an in vitro synergistic antimicrobial effect (reduction of 4 log–7 log CFU/mL) between meropenem and the lytic phage in all combinations analyzed (Ab105-2phi∆CI mutant at 0.1, 1 and 10 MOI and meropenem at 1/4 and 1/8 MIC). Moreover, bacterial growth was reduced by 8 log CFU/mL for the combination of imipenem at 1/4 MIC plus lytic phage (Ab105-2phi∆CI mutant) and by 4 log CFU/mL for the combination of imipenem at 1/8 MIC plus lytic phage (Ab105-2phi∆CI mutant) at both MOI 1 and 10. These results were confirmed in an in vivo model (G. mellonella), and the combination of imipenem and mutant Ab105-2phi∆CI was most effective (p < 0.05). This approach could help to reduce the emergence of phage resistant bacteria and restore sensitivity to antibiotics used to combat multi-resistant strains of Acinetobacter baumannii.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acinetobacter baumanniiAntibiotic-phage synergyMultiresistantMutant lytic phagePhage therapyMeropenemAcinetobacter baumanniiDatabases, nucleic acidPhage therapyAnti-bacterial agentsImipenemBacteriophagesMeropenemAcinetobacter baumanniiDatabases, nucleic acidPhage therapyAnti-bacterial agentsImipenemResearch article31726694open accessBacteriophagesAntibacterianosBacteriófagosBases de datos de ácidos nucleicosTerapia de fagos10.3390/microorganisms7110556PMC6921023https://www.mdpi.com/2076-2607/7/11/556/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921023/pdf